GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (STU:8BT) » Definitions » Additional Paid-In Capital

BriaCell Therapeutics (STU:8BT) Additional Paid-In Capital : €0.00 Mil(As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BriaCell Therapeutics Additional Paid-In Capital?


BriaCell Therapeutics's quarterly additional paid-in capital increased from Jul. 2023 (€6.71 Mil) to Oct. 2023 (€7.50 Mil) but then stayed the same from Oct. 2023 (€7.50 Mil) to Jan. 2024 (€0.00 Mil).

BriaCell Therapeutics's annual additional paid-in capital increased from Jul. 2021 (€1.84 Mil) to Jul. 2022 (€5.14 Mil) and increased from Jul. 2022 (€5.14 Mil) to Jul. 2023 (€6.71 Mil).


BriaCell Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for BriaCell Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Additional Paid-In Capital Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.84 5.14 6.71

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.13 6.28 6.71 7.50 -

BriaCell Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

BriaCell Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (STU:8BT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (STU:8BT) Headlines

No Headlines